Gilead Sciences Inc yesterday said that it would charge the US government and other developed countries US$390 per vial for its coronavirus-fighting drug remdesivir, or about US$2,340 for a typical five-day course of treatment.
Gilead said in a statement that it would offer this price to developed countries around the world, to create a one-price model that would avoid the need for country-by-country negotiations, which could slow down access.
“We wanted to make sure that nothing gets in the way of remdesivir getting to patients,” Gilead chief executive officer Daniel O’Day said in an interview.
The price “will make sure all patients around the world have access to this medicine,” O’Day said.
The US$390 per vial price is for government entities. Once supply is less tight and Gilead starts selling the drug in normal distribution channels, the list price for private insurance companies and other commercial payers in the US would be US$520 a vial, or US$3,120 for a five-day course.
Remdesivir is one of the first widely used drugs for COVID-19. It received an emergency-use authorization from US regulators last month, after a big trial found the medicine sped recovery by about four days in hospitalized patients.
Hundreds of treatments and vaccines are in development worldwide as researchers race to find ways to halt a global pandemic that has infected more than 10 million people and killed more than 500,000.
Gilead had promised to donate its supply of the drug until the end if this month, but what the company would charge after the donation runs out has been furiously debated.
The drugmaker’s pricing decision is consequential because it sets a precedent for how much future medicines for COVID-19 might cost.
The company said that it could have charged more based on the value the medicine provides, the typical approach drugmakers use in setting pricing for new and innovative therapies.
Remdesivir could save US$12,000 per patient by getting people out of the hospital faster, but it went with a lower price to make sure that all developed countries could afford it, Gilead said.
Some estimates have found that remdesivir would be cost-effective at as much as US$4,500 for a treatment course.
Other advocates, including consumer-rights group Public Citizen, have said that the drug should just cost US$1 a day based on calculations that it could be manufactured at scale by generic drugmakers for that amount.
In the interview, O’Day said that US$1 per day was “not a realistic price point.”
Six vials of remdesivir are used during a five-day treatment, but a minority of patients need 10 days of treatment, or 11 vials, which would bring the total cost up to US$4,290.
Pricing of the drug was a balancing act, O’Day said.
On the one hand, a pandemic is raging and there is no cure. On the other, the company is a for-profit entity that has invested enormously in manufacturing large quantities of the medicine quickly, as well as developing new, easier-to-administer versions, he said.
WIN-WIN SITUATION: Customers, products and client portfolios of the companies are complementary, allowing for inroads into new fields, Chipbond’s chairman said Chipbond Technology Corp (頎邦) yesterday said it plans to acquire about a 31 percent stake in Orient Semiconductor Electronics Ltd (華泰電子) in a cash-and-share deal, aiming to make inroads into flash memory-chip packaging. Chipbond said the strategic alliance would open the door for the company to enter the flash memorychip packaging and testing market, which is a new business for the Hsinchu-based company. Chipbond primarily provides testing and packaging services for driver integrated circuits that are used in flat panels. BUSINESS OPPORTUNITY “Except for flash memory chips, we also saw a lot of new businesses that require the technologies of Chipbond or Oriental
MOMENTUM: While next-generation smartphones feature more semiconductors and vendors increase their inventory, the chipmaker remains focused on production in Taiwan Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the sole chip supplier for Apple Inc’s iPhone series, yesterday raised its revenue forecast again, saying that robust demand for 5G smartphones and high-performance-computing (HPC) would help boost revenue this year by 30 percent in US dollar terms. Three months ago, the chipmaker estimated that revenue would grow 20 percent this year from last year, reaching its long-term growth target of 15 to 20 percent annually. “Moving into the fourth quarter, we expect our growth in revenue to be supported by strong demand for our industry-leading 5-nanometer technology driven by 5G smartphone launches and HPC-related applications,”
Luxury hotel Mandarin Oriental Taipei (文華東方酒店) plans to reopen its guestrooms in December to take advantage of a boom in domestic travel. The reopening would come six months after the five-star facility suspended room operations to cut costs as countries across the region impose border controls to contain the COVID-19 pandemic, diminishing demand for business travel. “We are delighted to share that Mandarin Oriental Taipei will resume room operations on December 1,” the hotel said in a statement yesterday. The hotel in Songshan District (松山) said it would adopt stringent health and safety practices to ensure the well-being of its guests and employees. It
India’s COVID-19 economic gloom turned into despair this week, on news that its per capita GDP for this year might be lower than that of Bangladesh. “Any emerging economy doing well is good news,” Kaushik Basu, a former World Bank chief economist, said on Twitter after the IMF updated its World Economic Outlook. “But it’s shocking that India, which had a lead of 25% five years ago, is now trailing.” Ever since it began opening up the economy in the 1990s, India’s dream has been to emulate China’s rapid expansion. After three decades of persevering with that campaign, slipping behind Bangladesh hurts